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Evidence of association of the
NLRP1 gene with giant cell arteritis
Recent studies have focused attention on the involvement of
NLRP1 to confer susceptibility for extended autoimmune/
inﬂammatory disorders, being considered a common risk factor
in autoimmunity.1–3 NLRP1 provides a scaffold for the assembly
of the inﬂammasome that activates caspases 1 and 5, required
for processing and activation of the proinﬂammatory cytokines
interleukin 1β (IL-1β), IL-18 and IL-33 and promoting inﬂamma-
tion.4 In this study, we examined for the ﬁrst time whether
NLRP1 is associated with giant cell arteritis (GCA), a chronic
systemic vasculitis affecting large and medium-sized arteries
derived from the aorta, in particular the cranial branches of the
carotid artery. GCA is the most common vasculitis in the elderly
in Western countries with a female predominance.5 To investi-
gate the possible genetic association of NLRP1 with this disease,
we genotyped a single-nucleotide polymorphism (rs8182352),
which has been reported to confer risk to the development of
autoimmune processes in previous studies,1 2 in a total of 3583
individuals, comprising a discovery set from Spain (574 patients
diagnosed with biopsy-proven GCA and 2366 healthy controls)
and a replication set of subjects from Italy (111 biopsy-proven
GCA patients and 532 controls) using a predesigned TaqMan
allele discrimination assay. All individuals were of European
Caucasian origin. Patients were stratiﬁed according to the pres-
ence or absence of polymyalgia rheumatica, visual ischaemic
manifestations and irreversible occlusive disease, as previously
described.6 7 Approval from the local ethical committees and
informed written consent from all participants were obtained.
The analysed genetic variant rs8182352 showed statistically sig-
niﬁcant differences between GCA patients and unaffected
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controls in the Spanish cohort (p=0.012, OR=1.18, CI 95%
=1.04 to 1.34) and in the combined meta-analysis
(p=2.62×10−3, OR=1.20, CI 95%=1.06 to 1.35) including the
Italian cohort (ﬁgure 1). Moreover, homozygous carriers of the
allele C+ allele C (CC) genotype evidenced increased GCA risk
in the combined data in comparison with non-CC carriers
(p=9.6×10−3, OR=1.29, CI 95%=1.07 to 1.55). Despite their
different geographical origin, we previously reported no differ-
ences in the clinical spectrum of the disease between both popu-
lations,8 and the combinability test according to Breslow–Day
method showed no signiﬁcant heterogeneity in the ORs. When
cases were meta-analysed against controls according to the spe-
ciﬁc clinical features of GCA, only a signiﬁcant association with
visual ischaemic manifestations was observed (p=0.014,
OR=1.29, CI 95%=1.05 to 1.58). In addition, no statistically
signiﬁcant differences were observed when the subphenotype
analysis was performed comparing GCA patients positive
against those negative for the analysed clinical characteristic
(data not shown).
This study shows for the ﬁrst time that NLRP1 rs8182352, a
polymorphism with no predicted functional role, is associated
with GCA in two different European populations. It has been
proposed that NLRP1 is an important regulator of different
inﬂammatory and autoimmunity processes, mainly because of
its ability to form the inﬂammasome that plays a pivotal role
in the activation of IL-18 and IL-33.4 Previous studies evidenced
that IL-18, which is expressed by a wide range of immune cells
and can mediate both Th1 and Th2 driven immune responses,
contributes to the pathogenesis of GCA.9 Furthermore, this vas-
culitis is associated with increased inﬂammatory response,6 and
IL-33 has been characterised as a critical component of the
inﬂammatory disease, with immune cell activation.10
In conclusion, we have identiﬁed NLRP1 as a novel GCA sus-
ceptibility gene, thus adding another piece to the genetic
puzzle underlying the pathogenesis of this complex disease.
Our data suggest that the inﬂammasome may represent a
potential target for future therapeutic intervention. However,
further studies may be performed to elucidate the possible
causal variant/s of this association and its functional conse-
quence, which is a limitation of this study.
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Figure 1 Genotype distribution and minor allele frequency (MAF) of the NLRP1 polymorphism rs8182352 in giant cell arteritis (GCA) patients and
healthy controls from Caucasian Spanish and Italian populations. The overall statistical power of the analysis was 88% to detect associations with
OR=1.2 at the 5% signiﬁcant level, according to Power Calculator for Genetic Studies 2006 software (http://www.sph.umich.edu/csg/abecasis/CaTS/).
After genotyping, no evidence of departure from Hardy–Weinberg equilibrium was observed in either case or control populations (p=0.05). All
statistical analyses of allele frequencies were performed using Plink V.1.07 (http://pngu.mgh.harvard.edu/purcell/plink/). To test for associations, p
values were obtained by performing 2×2 contingency tables and χ2 test and/or Fisher’s exact test, when appropriate. ORs and 95% CI were calculated
according to Woolf ’s method. p Values lower than 0.05 were considered as statistically signiﬁcant. Combined OR was calculated according to a
ﬁxed-effects model (Mantel–Haenszel meta-analysis) and the heterogeneity of the ORs among all populations was calculated using the Breslow–Day
test. The forest plot was performed with StatsDirect V.2.4.6 (Altrincham, UK). *p Value for the allelic model. **OR for the minor allele.
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